Citations

Clear

225 citation(s) found for "Ryu, Jay H".

Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, Harold R. , Moore, Bethany B. , Flaherty, Kevin R. , Brown, Kevin M. , King, Talmadge E. , Lasky, Joseph A. , Loyd, James E. , Noth, Imre , Olman, Mitchell A. , Raghu, Ganesh , Roman, Jesse , Ryu, Jay H. , Zisman, David A., Hunninghake, Gary W., Colby, Thomas V. , Egan, Jim, Hansell, David M., Johkoh, Takeshi , Kaminski, Naftali , Kim, Dong Soon, Lynch, David A. , Müller–Quernheim, Joachim, Selman, Moisés , Toews, Galen B., Wells, Athol U. , Kaner, Robert J. , Kondoh, Yasuhiro , Myers, Jeffrey L. , Nicholson, Andrew G. , Martínez, Fernando J. , Kaminski, Naftali , Ryu, Jay H , Loyd, James E

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 21, 2007 | Volume: 176 | Issue: 7 | Pages: 636-643

10.1164/rccm.200703-463pp | PMID 17585107 Get It

Abstract The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady, predictable decline in lung function over time. Recent evidence suggests that some patients may experience a more precipitous course, with periods of relative stability followed by acute deteriorations in respiratory status. Many of these acute deteriorations are of unknown etiology and have been termed acute exacerbations of IPF. This perspective is the result of an international effort to summarize the current state of knowledge regarding acute exacerbations of IPF. Acute exacerbations of IPF are defined as acute, clinically significant deteriorations of unidentifiable cause in patients with underlying IPF. Proposed diagnostic criteria include subjective worsening over 30 days or less, new bilateral radiographic opacities, and the absence of infection or another identifiable etiology. The potential pathobiological roles of infection, disordered cell biology, coagulation, and genetics are discussed, and future research directions are proposed.
CT Findings of Granulomatous Pneumonitis Secondary to Mycobacterium avium-intracellulare Inhalation: “Hot Tub Lung”
Hartman, Thomas E. , Jensen, Eric A., Tazelaar, Henry D. , Hanak, Viktor, Ryu, Jay H. , Tazelaar, Henry D. , Ryu, Jay H

Mayo Clinic

American Journal of Roentgenology | March 21, 2007 | Volume: 188 | Issue: 4 | Pages: 1050-1053

10.2214/ajr.06.0546 | PMID 17377045 Get It

The NHLBI Lymphangioleiomyomatosis Registry
Ryu, Jay H. , Moss, Joel , Beck, Gerald J. , Lee, Jar-Chi, Brown, Kevin K. , Chapman, Jeffrey T., Finlay, Geraldine A., Olson, Eric J. , Ruoss, Stephen J. , Maurer, J.R., Raffin, Thomas A., Peavy, Hannah, Taveira‐DaSilva, Angelo M., McCormack, Francis X. , Avila, Nilo A., DeCastro, Rosamma, Jacobs, Susan S. , Stylianou, Mario, Fanburg, Barry L., Lee, Jar-Chi, McCarthy, Kevin , McCormack, Francis X , Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 6, 2005 | Volume: 173 | Issue: 1 | Pages: 105-111

10.1164/rccm.200409-1298oc | PMID 16210669 Get It

Abstract Rationale Pulmonary lymphangioleiomyomatosis is a progressive cystic lung disease that is associated with infiltration of atypical smooth muscle–like cells. Previous descriptions of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited number of patients. Objectives To describe the clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis–related forms. Methods Over a 3-yr period, from 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national registry; 13 subjects who had already undergone lung transplantation were excluded for the purposes of this report. Measurements and Main Results All 230 subjects were women, aged 18 to 76 yr (mean ± SE, 44.5 ± 0.65 yr). The average age at onset of symptoms was 38.9 ± 0.73 yr and at diagnosis was 41.0 ± 0.65 yr. Tuberous sclerosis complex was present in 14.8% of subjects. Pulmonary manifestations, most commonly spontaneous pneumothorax, were the primary events leading to the diagnosis in 86.5% of cases. Nearly 55% of the subjects were being treated with a progesterone derivative. An obstructive pattern on pulmonary function testing was observed in 57.3% of the subjects, whereas 33.9% had normal spirometric results. Women with tuberous sclerosis–related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form. Conclusions The age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appreciated and the degree of pulmonary function can be quite variable, with one-third of subjects having normal spirometry at enrollment into this registry.
Bronchiolar Disorders
Ryu, Jay H. , Swensen, Stephen J., Myers, Jeffrey L. , Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 25, 2003 | Volume: 168 | Issue: 11 | Pages: 1277-1292

10.1164/rccm.200301-053so | PMID 14644923 Get It

Abstract Bronchiolar abnormalities are relatively common and occur in a variety of clinical settings. Various histopathologic patterns of bronchiolar injury have been described and have led to confusing nomenclature with redundant and overlapping terms. Some histopathologic patterns of bronchiolar disease may be relatively unique to a specific clinical context but others are nonspecific with respect to either etiology or pathogenesis. Herein, we present a scheme separating (1) those disorders in which the bronchiolar disease is the predominant abnormality (primary bronchiolar disorders) from (2) parenchymal disorders with prominent bronchiolar involvement and (3) bronchiolar involvement in large airway diseases. Primary bronchiolar disorders include constrictive bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse panbronchiolitis, respiratory bronchiolitis, mineral dust airway disease, follicular bronchiolitis, and a few other rare variants. Prominent bronchiolar involvement may be seen in several interstitial lung diseases, including hypersensitivity pneumonitis, respiratory bronchiolitis–associated interstitial lung disease, cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulmonary Langerhans' cell histiocytosis. Large airway diseases that commonly involve bronchioles include bronchiectasis, asthma, and chronic obstructive pulmonary disease. The clinical relevance of a bronchiolar lesion is best determined by identifying the underlying histopathologic pattern and assessing the correlative clinico–physiologic–radiologic context.
Outcome of Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit
Saydain, Ghulam , Islam, Ashiq, Afessa, Bekele, Ryu, Jay H. , Peters, Steve G. , Scott, James G. , Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | September 13, 2002 | Volume: 166 | Issue: 6 | Pages: 839-842

10.1164/rccm.2104038 | PMID 12231494 Get It

Abstract This retrospective study describes the clinical course of 38 patients with idiopathic pulmonary fibrosis (IPF) admitted to the intensive care unit (ICU). There were 25 males and 13 females who were the mean age of 68.3 ± 11.5 years. Twenty patients were on corticosteroids at the time of admission to the hospital, and 24 had been on home oxygen therapy. The most common reason for ICU admission was respiratory failure. The Acute Physiology and Chronic Health Evaluation III–predicted ICU and hospital mortality rates were 12% and 26%, whereas the actual ICU and hospital mortality rates were 45% and 61%, respectively. We did not find significant differences in pulmonary function or echocardiogram findings between survivors and nonsurvivors. Mechanical ventilation was used in 19 patients (50%). Sepsis developed in nine patients. Multiple organ failure developed in 14% of the survivors and in 43% of the nonsurvivors (p = 0.14). Ninety-two percent of the hospital survivors died at a median of 2 months after discharge. These findings suggest that patients with IPF admitted to the ICU have poor short- and long-term prognosis. Patients with IPF and their families should be informed about the overall outlook when they make decisions about life support and ICU care.